Ben Wylie, senior product manager at ChargePoint Technology, argues that single-use (SU) technology is central to helping biotechs optimise efficiency in order to meet fast-growing demand for biologic treatments.
Biopharma
The biopharma sector is expanding faster than ever before. In Europe alone, the market is expected to grow at a CAGR of 8.89% to reach $67.76 billion by 2025, up from $44.26 billion at the end of 2020. This rise in demand for biologic treatments is being driven primarily by growing diagnoses worldwide of chronic conditions, such as diabetes and cancer, particularly in North America and Europe, where populations are ageing rapidly.
The growth in the biopharma sector in recent years has led to a significantly increase in the need for aseptic manufacturing in turn. As a result, the sterile processing market was estimated to be worth $62.2 billion in 2020, and is expected to expand considerably over the next half decade to meet rising biologic demand.